Skip to main contentSkip to navigationSkip to search

Our approach

Partners for change

A commitment that goes beyond products

Camurus takes its commitment to improve quality of life for patients with severe and chronic diseases seriously and we believe we have a role to play that extends far beyond developing and commercialising pharmaceutical products.

Our daily work with healthcare professionals and healthcare organisations combined with our science-led therapy expertise, gives us a valuable perspective of the opioid dependence treatment (ODT) landscape and the challenges and obstacles that can stand in the way of innovation and change.

We are also fortunate to witness many examples of outstanding work to improve patient access and treatment in the field of ODT. We firmly believe we have an obligation to share these examples of best practice, so that more treatment providers and their patients can benefit from these innovative approaches.

Collaborative and joint working initiatives

It is widely acknowledged that pharmaceutical companies like Camurus can bring much-needed expertise, skills and resources to complement the expertise of healthcare organisations and patient organisations in the efforts to improve patient care.

Cross-sector engagement of this nature is often co-ordinated through Collaborative and Joint Working initiatives.

Joint working is a specific type of cross-sector project focused on direct benefit to patients.

Collaborative working is a new, broader category of cross-sector working where there is benefit to the NHS with patient care either maintained or improved.

Read about our recent collaborative and joint working initiatives

Transparency in everything we do

Our work with healthcare professionals, healthcare organisations and patients/patient groups carries a duty to be fully transparent about the nature of these relationships and activities. Camurus is fully committed to compliance. We work within all applicable laws and voluntarily operate within the principles of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice.


We document and publicly disclose certain transfers of value (ToVs) made directly or indirectly to healthcare professionals (HCPs), healthcare organisations (HCOs) and other relevant decision makers (ORDMs) located in Europe, as well as to research & development (R&D) projects and patient organisations.

HCPs, HCOs and ORDMs

For details of our interactions with and payments to HCPs, HCOs and ORDMs, please refer to the ABPI Disclosure Database.

ABPI Disclosure Database.

Patients organisations, patients, the public and media

For details of our interactions with and payments to patients organisations, patients, the public or media please view the following declarations:

Camurus Ltd Disclosure 2020

Camurus Ltd Disclosure 2021

Camurus Ltd Disclosure 2022

Clinical trials and results

Details of ongoing and completed phase I to IV clinical trials run by Camurus are available to view on the following public websites:

Results of Camurus trials are also published on these websites and in peer reviewed journals. 

Investing in education and skills

Camurus is committed to the development of the healthcare workforce through education and training. We invest in programmes that give the opportunity for HCPs working in various roles within the field of drug and alcohol addiction, to broaden their knowledge and skills

Support to attend a third party educational event/meeting

As part of our commitment to support the continuing medical education of Healthcare Professionals (HCPs) working within the field of drug and alcohol addiction, Camurus dedicates a defined amount of funding each year to support individual HCPs with registration fees to attend selected third party meetings or conferences.

To ensure that sponsorship is awarded in an ethical, transparent and fair manner, we support HCP’s whose applications for funding meet criteria according to UK compliance guidelines and our own internal policies. Due to the finite budget associated with this support, we also operate on a first come, first served basis, and therefore good applications may still be denied, where funding is no longer available.

Where Camurus does agree to support an HCP with registration fees to attend third party meetings, under no circumstances does Camurus wish to receive anything in return. The support is not offered as an inducement to prescribe, supply, administer, recommend, buy or sell a Camurus medicine nor is the offer of support linked to any promotional activity (for example the requirement to attend a promotional presentation or symposium at the third party meeting).

Camurus is transparent in how we interact with the healthcare system. Camurus will publicly disclose each sponsorship as a ‘Transfer of Value’  in keeping with industry standards. We do this via the industry body disclosure portal:

Recipients will be required to sign a Sponsorship Agreement acknowledging the terms of the sponsorship, including the requirement for disclosure.

Criteria and application process

UK-NPR-2300117  Nov 2023